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Phosphoprotein phosphatase inhibitor-2 (i-2) was rapidly isolated from mouse diaphragm extracts by the 
use of specific antibodies. The i-2 so obtained was associated with ATP-Mg and F*/GSK-3 dependent phos- 
phatase activity, supporting the idea that i-2 is in fact a component of this form of phosphatase. Inhibitor-2 
isolated from diaphragms incubated with [3ZP]phosphate contained both phosphoserine (_ 90%) and phos- 
phothreonine (N 10%). Therefore, i-2 is multiply phosphorylated in mouse diaphragm and the potential 
exists for control of the ATP-Mg-dependent phosphatase via multiple phosphorylation sites in vivo. 
A TP-Mg-dependent phosphatase Antibody Type I phosphatase Protein phosphorylation 
Mouse diaphragm 
1. INTRODUCTION 
Inhibitor-2 is a heat stable protein [1,2] able to 
inhibit phosphoprotein phosphatase of type 1 
[3,4]. Recently it has been found to be a compo- 
nent [5] of the ATP-Mg-dependent phosphatase 
first described by Riley and Haynes [6], and later 
by Merlevede and Riley [7]. This enzyme requires 
a protein factor, FA, and ATP-Mg [8,9] to elicit ac- 
tivity. The proposed mechanism is that FA, also 
identified as a glycogen synthase kinase GSK-3 
[lo], phosphorylates the inhibitor-2 [ll], in the 
ATP-Mg-dependent phosphatase, at a threonine 
residue. This phosphorylation causes a conforma- 
tional change of the catalytic component [12,13], 
leading to activation of the phosphatase. Phos- 
phorylation of inhibitor-2 at serine residues in vivo 
has also been reported. Casein kinase II is able to 
phosphorylate the inhibitor whether in an isolated 
form or as part of the ATP-Mg-dependent phos- 
phatase complex [ 141. This phosphorylation occurs 
at serine residues and by itself does not affect en- 
zyme activity. However, the action of casein kinase 
II in combination with submaximal concentrations 
of F&&SK-3 greatly enhances phosphorylation by 
the latter protein kinase and the activation of the 
Inhibitor-2 
phosphatase. Cyclic AMP-dependent protein 
kinase also phosphorylates inhibitor-2 at serine 
residues but without detectable ffect on the pro- 
perties of the phosphatase [14]. The possibility ex- 
ists, therefore, that inhibitor-2 might undergo mul- 
tiple phosphorylation and this work was aimed at 
analyzing the phosphorylation state of inhibitor-2 
in mouse diaphragms by the use of specific an- 
tibodies. The study also provides direct evidence 
for an association of inhibitor-2 and phosphatase 
activity in rapidly processed extracts. 
2. MATERIALS AND METHODS 
2.1. Materials 
[32P]Orthophosphate was purchased from New 
England Nuclear. Staphylococcus aureus of strain 
Cowan 1 (Pansorbin) was obtained from Calbio- 
them-Behring. CNBr-activated Sepharose-4B and 
other chemicals were from Sigma. Mice of strain 
ICR were from Harlan (Indianapolis). Phosphatase 
inhibitor-2 was purified from rabbit skeletal mus- 
cle as in [14]. [32P]Phosphorylase a was prepared 
as in [14]. Catalytic subunit of type 1 phosphatase 
was purified to homogeneity by a modification of 
the procedures in [4,15]. Analysis by polyacryl- 
Published by Ekevier Science Publishers B. V. (Biomedical Division) 
00145793/85/$3.30 0 1985 Federation of European Biochemical Societies 423 
Volume 183, number 2 FEBS LETTERS April 1985 
amide gel electrophoresis (PAGE) in the presence 
of SDS indicated that the preparation contained a 
single polypeptide of apparent M, 38 000. No other 
species of lower il4, were observed. The specific ac- 
tivity of the phosphatase was 27 000 units/mg (unit 
as defined in 1141). Phosphatase and inhibitor-2 
assays and the phosphorylation of inhibitor-2 by 
casein kinase II [16] were performed as in [14]. 
2.2. Preparation and affinity purification of anti- 
bodies against phosphatase inhibitor-2 
Antibodies against inhibitor-2 were raised in 
guinea pigs as described in [17]. For each injection 
the animals received 80 pug purified protein. Both 
immune serum and affinity purified antibodies 
were used here. Inhibitor-2 was coupled to CNBr- 
activated Sepharose and this matrix was used for 
affinity purification of the antibodies from the 
serum. The specificity of the antibodies was deter- 
mined by their ability to immunoprecipitate 32P- 
labeled inhibitor-2 phosphorylated up to 3 mol 
phosphate per mol inhibitor by casein kinase II. 
32P-labeled inhibitor removal after treatment with 
S. aureus was measured as well as the amount 
associated with the immunoprecipitate. All of the 
inhibitor-2 could be precipitated by the antibodies 
and recovered in the immunoprecipitates, as a 
species of Mr 32 000 as judged by SDS-PAGE (not 
shown). Also, addition of unlabeled inhibitor-2 
before exposure to the antibodies reduced the 
amount of 32P-labeled inhibitor associated with the 
immunoprecipitate. This competition experiment 
established that the antibodies recognized both 
phosphorylated and unphosphorylated inhibitor-2. 
2.3 Incubation of mouse diaphragm and immuno- 
precipitation of phosphatase inhibitor-2 
Diaphragm muscles from male mice (22-26 g) 
were carefully excised and incubated in 1 ml of 
medium containing 119 mM NaCl, 4.6 mM KCI, 
1.2 mM MgS04,2.4 mM CaCl2,O. 1 mM KHzP04, 
24.8 mM NaHCO3 and 5 mM glucose. Each in- 
cubation contained two diaphragms and was car- 
ried out under an atmosphere of 95% 02 : 5% COZ. 
After 10 min preincubation the muscles were 
transferred to flasks containing 1 ml fresh medium 
and 0.7 mCi [32P]phosphate was added. Incuba- 
tions were continued for 1 h after which the tissues 
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were frozen in liquid nitrogen. Homogenization 
was performed in 5 vols of 50 mM Tris-HCI, 100 
mm NaF, 10 mM EDTA, 2 mM EGTA, 2 mM 
KHzP04, 10 mM benzamidine, 0.5 mM phenyl- 
methylsulfonyl fluoride, 0.5 mM tosylphenyl- 
chloromethyl ketone, 0.1 mM tosyllysylchlorome- 
thy1 ketone, 10 pg/ml leupeptin and 0.1% Triton 
X-100, pH 7.2. After centrifugation at 13OOOxg 
for 20 min the supernatant was retained for im- 
munoprecipitations. Portions of the supernatants 
were heated at 100°C for 10 min followed by cen- 
trifugation as before. Untreated tissue extracts 
(125 ~1) or boiled supernatants (125 ~1) were in- 
cubated with antibodies (9.4 ~1 immune serum or 
9 pg affinity-purified IgG). These amounts were 
sufficient to achieve maximal removal of inhibitor-2 
from the tissue extracts. Controls contained the 
same amount of non-immune serum or purified 
non-immune IgG. After 30 min at room temper- 
ature, the samples were placed on ice and excess 
Pansorbin (5070, w/v, 140 ~1 for serum or 31 cl1 for 
purified IgG) was added, respectively. Following a 
30 min incubation at 0°C the bacterial pellet was 
collected by centrifugation at 3OOOxg for 5 min 
and washed twice by consecutive resuspension and 
centrifugation in buffer consisting of 10 mM 
sodium phosphate, 1 mM EDTA, 0.4 M NaCl, 
0.1% Triton X-100, pH 7.5. A third wash with 
NaCl reduced to 0.1 M was also included. To elute 
32P-labeled inhibitor-2, the pellet was either ex- 
tracted with 200 ~1 of 70% formic acid or 
resuspended in 50 mM Tris-Cl, 0.1 mM EDTA, 
125 mM P-mercaptoethanol and treated at 100% C 
for 10 min. The supernatant obtained after cen- 
trifugation at 8000 x g for 10 min was dried using 
a centrifugal evaporator (Speedvac, Savant In- 
struments). The samples were analyzed on 6-2% 
acrylamide gradient gels using a modification [18] 
of the procedure of Laemmli [19]. Phosphoamino 
acid analysis was also performed as described in 
[14]. For measurements of inhibitor-2, spon- 
taneously active phosphatase and ATP-Mg-de- 
pendent phosphatase, diaphragm muscles were in- 
cubated in the absence of [32P]phosphate. ATP- 
Mg-dependent phosphatase was determined as in 
[14] using a suspension of antigen-antibody-S. 
aureus complex. Inhibitor-2 was released from the 
antibody-protein A complex by treatment for 10 
min at 1OO’C in 50 mM Tris-HCl, 0.1 mM EDTA 
and 50 mM /3-mercaptoethanol, pH 7.0. The 
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bacteria were removed by centrifugation and the numerous polypeptides separated by SDS-PAGE 
supernatant was used to measure inhibitor-2 by its (fig.lA, track 1). As could be expected, many of 
ability to inhibit the low- Mr type 1 phosphatase. these labeled species were not detected in extracts 
that had been heat treated (fig.lA, track 2). An- 
3. RESULTS 
3 I . . “P labeling of phosphatase inhibitor-2 in 
mouse diaphragm 
Incubation of mouse diaphragms with [‘*PI- 
phosphate led to the incorporation of ‘*P into 
tibodies against purified rabbit skeletal muscle 
phosphatase inhibitor-2 were able to immunopre- 
cipitate inhibitor-2 from extracts of mouse dia- 
phragm incubated with [32P]phosphate (fig. 1B 
and C). Analysis of material released at 100°C 
from immunoprecipitates indicated a single, domi- 
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Fig.1. Analysis of immunoprecipitates from mouse diaphragms incubated with 13’P)phosphate. Tissue extracts or im- 
munoprecipitates prepared as described in section 2, were analyzed by polyacrylamide gel electrophoresis n the presence 
of SDS. Portions of a corresponding autoradiogram are shown. Panel A: unboiled (track 1) or boiled (track 2) extracts, 
equivalent to 1.25 mg tissue. Panel B shows material immunoprecipitated with affinity-purified antibodies and released 
from the bacterial pellet by heat treatment. Immunoprecipitates prepared from boiled (tracks 3 and 4) or unboiled 
(tracks 1 and 2) extracts, equivalent o 14 mg tissue were analyzed. Either antibodies (tracks 2 and 4) or a corresponding 
control (non-immune IgG) were used (tracks 1 and 3). Panel C, tracks l-4, shows the results of a similar analysis except 
that the immunoprecipitates were extracted with 70% formid acid. Panel C. tracks 5-8, shows results using serum for 
the immunoprecipitation and heat treatment for extraction of the bacterial pellet. Tracks 5 and 7, non-immune serum; 
tracks 6 and 8, immune serum; tracks 5 and 6, unboiled extract; tracks 7 and 8, boiled extract. The numbers denote 
M, values (x 10e3). 
425 
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nant radioactive species of Mr 32000, similar to 
that of purified inhibitor-2 (fig. 1B and C, tracks 
2,4,6 and 8). A much lesser proportion of a higher 
mobility species, apparent M, 34 000, was also visi- 
ble, as well as a species of apparent A4, 27500. 
These polypeptides were absent from control 
precipitations using non-immune IgG or serum 
(fig. 1B and C, tracks 1, 3, 5 and 7). Similar results 
were obtained whether the immunoprecipitate was 
derived from unboiled or boiled tissue extracts. In 
particular, the intensity of the radioactive band in 
both cases was very similar, suggesting that in- 
hibitor-2 was unaffected by the treatment of the 
extract at 100°C. Both immune serum and affinity 
purified antibodies immunoprecipitated the same 
dominant 32-kDa labeled polypeptide. Since it 
could be argued that proteins present in the im- 
munoprecipitates from unboiled extracts might 
become insoluble after boiling, the immunopre- 
cipitates were also extracted with 70% formic acid, 
in which most proteins would be expected to be 
soluble. As seen in fig. 1C (tracks l-4), no signifi- 
cant difference in the SDS-PAGE analysis resulted 
when affinity purified antibodies had been used. 
We did observe an additional 32P-labeled species of 
M, 43000, released by formic acid, when serum 
was used to prepare immunoprecipitates from un- 
boiled (but not boiled) extracts (not shown). As ex- 
plained below, the significance of this species is 
unclear. 
Competition experiments were also carried out 
to help confirm the identity of the 32-kDa species. 
Thus, different amounts of unlabeled rabbit mus- 
cle inhibitor-2 were added to boiled or unboiled ex- 
tracts before exposure to antibodies. As shown in 
fig. 2 for affinity-purified antibodies, the un- 
labeled inhibitor effectively competed with the 
32-kDa and 34-kDa 32P-labeled species in a 
concentration-dependent manner. The 27 500-kDa 
species did not compete (fig. 2) and in other ex- 
periments the 43-kDa species was not associated 
with the use of unfractionated serum (not shown). 
3.2. Phosphoamino acid analysis of 32P-labeled 
inhibitor-2 
Inhibitor-2 immunoprecipitated from boiled ex- 
tracts by affinity-purified antibodies (thus lacking 
the 27-kDa species) was subjected to acid hydro- 
lysis and the resulting 32P-labeled amino acids were 
analyzed by thin-layer electrophoresis. Autoradio- 
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Fig. 2. Competition of the immunoprecipitated mouse 
inhibitor-2 with rabbit inhibitor-2. Immunoprecipitates 
were prepared as described for fig.1 from unboiled 
(tracks l-5) or boiled (tracks 6-10) extracts of 32P- 
labeled mouse diaphragms. Before exposure to affinity- 
purified antibodies, purified rabbit skeletal muscle 
inhibitor-2,0 (tracks 1 and 6), 50 ng (tracks 2 and 7), 150 
ng (tracks 3 and 8), 450 ng (tracks 4 and 9) or 900 ng 
(tracks 5 and 10) were added to the extracts. Shown is an 
autoradiogram prepared after SDS-polyacrylamide gel 
electrophoresis of the material released from the 
bacterial pellet by heat treatment. The numbers 
alongside the gel represent M, values (X 10d3). 
graphy of the plate showed that most of the radio- 
activity was associated with phosphoserine and on- 
ly a small amount, approx. lo%, was present as 
phosphothreonine (fig. 3B). Only a trace of phos- 
phoserine was associated with the corresponding 
non-immune IgG. In fig. 3A is shown the analysis, 
by SDS-PAGE and autoradiography, of the 
material used for the phosphoamino acid deter- 
minations shown in fig. 3B. 
3.3. A TP-Mg-dependent phosphatase and inhibi- 
tor-2 activity associated with the immunopre- 
cipitates 
Immunoprecipitates obtained with unboiled 
mouse diaphragm extracts were analyzed for both 
Volume 183, number 2 FEBS LETTERS April 1985 
ATP-Mg-dependent phosphatase activity and 
phosphatase inhibitory material (table 1). Little or 
no spontaneously active phosphatase was detected 
whereas in the presence of FJGSK-3 and ATP-Mg 
significant activity was measured. Heat treatment 
i-2 
123456 
-r(P) 
h-(P) 
Table 1 
Analysis of phosphatase and inhibitor-2 activity in im- 
munoprecipitates of mouse diaphragm extracts 
Phosphatase Inhibitor-2 activity 
activity (070 inhibition) 
(units/ml) 
FA/GSK-~ 
- + 
Immune IgG 0.05 3.10 66 
Non-immune IgG 0.0 0.0 5 
Immunoprecipitates from unboiled diaphragm extracts 
(equivalent to 2 mg tissue) were analyzed for 
phosphatase and inhibitor-2 activity as described in sec- 
tion 2. The entries under ‘inhibitor-2 activity’ indicate 
the percentage inhibition of an assay containing 7.5 
munits of purified rabbit muscle type 1 phosphatase, 1 
unit corresponding to 1 nmol of 32Pr released per min 
of the bacterial pellets released material that was 
able to inhibit purified rabbit muscle type 1 phos- 
phatase. The parallel analyses for non-immune 
IgG indicated neither phosphatase activity nor 
phosphatase inhibitor associated with the S. 
aureus. 
- 
Fig. 3. Phosphoamino acid analysis of immunopre- 
cipitated mouse diaphragm inhibitor-2. Immunopre- 
cipitates from boiled extracts of ‘*P-labeled diaphragms 
were prepared as described in section 2 using affinity- 
purified antibodies. Panel A shows an autoradiogram 
resulting from gel electrophoretic analysis of the 
material released from the bacterial pellet by heat treat- 
ment (tracks 3 and 5). The corresponding analyses with 
non-immune IgG are shown in tracks 2 and 4. Tracks 1 
and 6 contained purified rabbit muscle inhibitor-2 which 
had been phosphorylated using [“P]ATP and casein 
kinase II. Another portion of the material analyzed in 
tracks 2-5 was hydrolyzed, and subjected to thin-layer 
electrophoresis, as described in section 2. Panel B, 
autoradiogram of the thin-layer plate: track 1, control 
IgG; track 2, affinity-purified antibodies. The origin and 
the anode are indicated by 0 and + , respectively. The 
migration of phosphoserine (ser(P)) and phosphothreo- 
nine (thr(P)) standards is also noted. 
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4. DISCUSSION 
Here, we set out to examine the phosphorylation 
strate of the inhibitor in intact muscle cells by us- 
ing mouse diaphragm incubated with [32P]phos- 
phate. With the use of specific antibodies we were 
able to isolate rapidly a phosphorylated species of 
32 kDa from crude muscle extracts. This species 
was recognized by immune but not by non-immune 
IgG, could compete with purified inhibitor-2, and 
was able to inhibit purified type 1 phosphatase. 
These results argue strongly that the 32-kDa 
polypeptide was indeed inhibitor-2. The results 
also demonstrate immunological cross-reactivity 
between rabbit skeletal muscle and mouse 
diaphragm inhibitor-2. 
One of the most striking findings was that im- 
munoprecipitates prepared with inhibitor-2 an- 
tibodies contained detectable ATP-Mg-dependent 
phosphatase activity. This result, for which both 
mild and rapid isolation methods were employed, 
provides strong evidence for an association of 
inhibitor-2 with the type 1 phosphatase catalytic 
subunit in the cell. Such an association had been 
inferred previously only from studies using con- 
ventionally purified components, often subjected 
to relatively harsh purification steps. However, the 
possibility has also been raised by Tonks and 
Cohen [20] that ATP-Mg-dependent phosphatase 
‘may not exist in freshly prepared extracts’. More 
work is needed for unequivocal resolution of this 
important question but the present study does 
demonstrate that ATP-Mg-dependent phosphatase 
activity is detectable shortly after homogenization 
of mouse muscle. 
32P labeling clearly indicated that phosphoryla- 
tion of the inhibitor occurs in mouse diaphragm 
and that phosphate turns over on the time scale of 
the experiments. In addition, 32P was introduced 
into both phosphoserine and phosphothreonine. 
Therefore, a protein kinase(s) besides FA/GSK-3 
must be operating in the cell. Currently, only two 
possible candidates are known, cyclic AMP- 
dependent protein kinase and casein kinase II, 
since these two protein kinases have been shown to 
phosphorylate inhibitor-2 at serine residues [ 141. 
Since only casein kinase II action affected the pro- 
perties of the phosphatase, it is tempting to specu- 
late that the phosphoserine observed in association 
with inhibitor-2 in muscle cells might result from 
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casein kinase II action and that this protein kinase 
might have a functional role in regulating phos- 
phatase activity. In any event and whatever protein 
kinases are responsible, demonstration of phos- 
phoserine in inhibitor-2 implies that control of this 
protein is likely to involve multiple phosphorylation 
sites and an important question now raised is 
whether physiological controls of phosphatase ac- 
tivity, such as by insulin and epinephrine, are cor- 
related with alterations in serine and/or threonine 
phosphorylation. Future studies will address this 
question. 
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